Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg for Idiopathic Cardiomyopathy with PVB19 Persistence
NCT00892112Phase 3Completed
- Sponsor
- Prothya Biosolutions
- Start
- Nov 2009
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic cardiomyopathy (ICM) and parvovirus B19 infection comparing Intravenous Immunoglobulins with Placebo (2 arms). Primary endpoint: Change in cardiac ejection fraction at 6 months. Started Nov 2009; status: completed.
02
Drugs
Nanogam
03
Conditions
idiopathic cardiomyopathy (ICM)parvovirus B19 infection
Beyond the preview
Go deeper on NCT00892112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00892112.